

# Rapid Human Cystatin C ELISA Kit

(Catalog Number: 31241)

For the quantitative determination of human cystatin C  
concentrations in serum, plasma or urine samples

## **IMD (Hong Kong)**

Address: Unit 513, 5/F, Biotech Centre 2, No. 11 Science Park West Avenue,  
Hong Kong Science Park, Sha Tin, Hong Kong

Website: [www.immunodiagnostics.com.hk](http://www.immunodiagnostics.com.hk)

Email: [info@immunodiagnostics.com.hk](mailto:info@immunodiagnostics.com.hk)

Tel: (+852) 3502 2780

## **IMD (Canada)**

Address: 3330 Bayview Avenue, Block #6, Toronto, M2M 3R8, Ontario, Canada

Email: [info@immunodiagnostics.ca](mailto:info@immunodiagnostics.ca)

Tel: +1-437-886-5136

## TABLE OF CONTENTS

Contents	Page
INTRODUCTION	1
PRINCIPLE OF THE ASSAY	1
INTENDED USE	1
REAGENTS SUPPLIED	1
OTHER MATERIALS REQUIRED, BUT NOT PROVIDED	2
STORAGE	2
PREPARATION OF REAGENTS	2
PREPARATION OF STANDARDS AND SAMPLES	2
ASSAY PROCEDURE	3
CALCULATION	3
TYPICAL STANDARD CURVE	4
ASSAY CHARACTERISTICS	4
REFERENCES	5
SUMMARY OF ASSAY PROCEDURE	6

## **INTRODUCTION**

Human cystatin C (or cystatin 3), which is composed of 120 amino acid residues, belongs to the cystatins superfamily that inactivates lysosomal cysteine proteinases. As a strongly cationic and low-molecular weight (13.4 kDa) protein, it is almost freely filtered across the glomerular membrane, and is mainly used as a biomarker of kidney function. A growing body of evidence suggests that cystatin C is a more reliable biomarker of glomerular filtration rate than creatinine<sup>1-3</sup>. In addition to kidney disease, altered serum levels of cystatin C are associated with several types of cardiovascular disease, including myocardial infarction, stroke, heart failure, peripheral arterial disease and metabolic syndrome<sup>4-7</sup>. It also seems to play a role in brain disorders involving amyloid, such as Alzheimer's disease<sup>8,9</sup>. Furthermore, cystatin C has also been investigated as a prognostic marker in several forms of cancer<sup>10-12</sup>.

## **PRINCIPLE OF THE ASSAY**

This assay is a sandwich enzyme-linked immunosorbent assay (ELISA) designed for the quantitative detection of human cystatin C in samples in 1 hour. The microtiter plate is pre-coated with antibody specific to human cystatin C. Standards and samples are pipetted into the wells and any human cystatin C present is sandwiched by the immobilized antibody and a second horseradish peroxidase (HRP)-linked antibody specific to human cystatin C that is co-incubated with the samples. After wash step to remove any unbound substances, the HRP substrate solution is added and color develops in proportion to the amount of human cystatin C bound initially. The assay is stopped, and the optical density of the wells is determined using a micro-plate reader. Since the increases in absorbance are directly proportional to the amount of captured human cystatin C, the unknown sample concentration can be interpolated from a reference curve included in each assay.

## **INTENDED USE**

This Rapid Human Cystatin C ELISA kit is designed for quantification of human cystatin C in serum, plasma and urine samples.

## **REAGENTS SUPPLIED**

*Each kit is sufficient for one 96-well plate and contains the following components:*

1. Microtiter strips (96 wells), coated with antibody against human cystatin C
2. 10×Wash buffer, 30 mL
3. 5×Assay buffer, 30 mL
4. 100×Detection antibody solution, antibody against human cystatin C conjugated with horseradish peroxidase, 0.12 mL
5. Human cystatin C standard, 15 ng of native human cystatin C, lyophilized
6. Substrate solution, 12 mL, ready for use
7. Stop solution, 12 mL, ready for use
8. Plate cover

Website: [www.immunodiagnosics.com.hk](http://www.immunodiagnosics.com.hk)

E-mail: [info@immunodiagnosics.com.hk](mailto:info@immunodiagnosics.com.hk)(HK) /[info@immunodiagnosics.ca](mailto:info@immunodiagnosics.ca)(Canada)

Tel: +852 3502 2780 (HK) / +1-437-886-5136 (Canada)

**OTHER MATERIALS REQUIRED, BUT NOT PROVIDED**

1. Pipettes and pipette tips
2. 96-well plate or manual strip washer
3. Buffer and reagent reservoirs
4. Paper towels or absorbent paper
5. Plate reader capable of reading absorbency at 450 nm
6. Distilled water or deionized water
7. Horizontal micro-plate shaker capable of 600 rpm

**STORAGE**

The kit should be stored at 2-8°C upon receipt, and all reagents should be equilibrated to room temperature before use. Remove any unused antibody-coated strips from the human cystatin C microtiter plate, return them to the foil pouch and re-seal. Once opened, the strips may be stored at 2-8°C for up to one month.

**PREPARATION OF REAGENTS**

*Bring all reagents and materials to room temperature before assay.*

**A. 1×Assay buffer**

Prepare 1×Assay buffer by mixing the 5×Assay buffer (30 mL) with 120 mL of distilled water or deionized water. If precipitates are observed in the 5×Assay buffer bottle, warm the bottle in a 37°C water bath until the precipitates disappear. The 1×Assay buffer may be stored at 2-8°C for up to one month.

**B. 1×Wash buffer**


Prepare 1×Wash buffer by mixing the 10×Wash buffer (30 mL) with 270 mL of distilled water or deionized water. If precipitates are observed in the 10×Wash buffer bottle, warm the bottle in a 37°C water bath until the precipitates disappear. The 1×Wash buffer may be stored at 2-8°C for up to one month.

**C. 1×Detection antibody solution**

Spin down the 100×Detection antibody solution briefly and dilute the desired amount of the antibody 1:100 with 1×Assay buffer, 100 µL of the 1×Detection antibody solution is required per well. Prepare only as much 1×Detection antibody solution as needed. Return the 100×Detection antibody solution to 2-8°C immediately after the necessary volume is removed.

**PREPARATION OF STANDARDS AND SAMPLES**

**Human Cystatin C Standards:** Reconstitute the lyophilized standard with 1 mL of 1×Assay buffer to generate a standard stock solution of 15 ng/mL. Allow the standard to sit for 10 minutes with gentle agitation prior to making dilutions. Prepare serially diluted standards using 1×Assay buffer as shown below.



1×Assay buffer serves as the zero standard (0 ng/mL). The reconstituted standard stock should be aliquoted and frozen at  $-20^{\circ}\text{C}$  for one month. Avoid repeating freezing/thawing cycles. Please do not store the diluted standard solutions.

**Sample Preparation:**

Serum or plasma sample generally requires a **160-fold** dilution in this assay. A suggested dilution step is to add 5 µL of serum or plasma sample to 795 µL of 1×Assay buffer. Urine sample generally requires a **20-fold** dilution. A suggested dilution step is to add 50 µL of urine sample to 950 µL of 1×Assay buffer. It is recommended that the users establish their own dilution factors based on the concentration range of their samples.

**ASSAY PROCEDURE**

*It is recommended that all standards and samples be assayed in duplicate.*

1. Add 100 µL of standard or sample per well.
2. Add 100 µL of the 1×Detection antibody solution to each well, seal the plate with a plate cover. Incubate at room temperature for 30 minutes, shaking the plate at 600 rpm on a horizontal micro-plate shaker.
3. Discard the content and tap the plate on a clean paper towel to remove residual solution in each well. Add 300 µL of 1×Wash buffer to each well and incubate for 1 minute. Discard the 1×Wash buffer and tap the plate on a clean paper towel to remove residual wash buffer. Repeat the wash step for a total 4 washes.
4. Add 100 µL of Substrate solution to each well. Incubate at room temperature for 15 minutes. **Protect from light.**
5. Add 100 µL of Stop solution to each well, gently tap the plate frame for a few seconds to ensure thorough mixing.
6. Measure absorbance of each well at 450 nm immediately.

**CALCULATION**


1. Subtract the absorbance of the blank from that of standards and samples.
2. Generate a standard curve by plotting the absorbance obtained (y-axis) against human cystatin C concentrations (x-axis). The best fit line can be generated with any curve-fitting software by regression analysis. Any curve of 4-parameter or log-log curve fitting can be used for calculation.
3. Determine human cystatin C concentration of samples from standard curve and multiply the value by the dilution factor.

**TYPICAL STANDARD CURVE**

The following standard curve is provided for demonstration only. A standard curve should be generated for each set of sample assay.

Cystatin C (ng/mL)	Absorbance (450 nm)	Blanked Absorbance
0	0.069	0
0.23	0.127	0.058
0.46	0.187	0.118
0.93	0.309	0.24
1.87	0.539	0.47
3.75	0.946	0.877
7.5	1.685	1.616
15	2.551	2.482

Human cystatin C standard curve (4-parameter)



**ASSAY CHARACTERISTICS**

**A. Sensitivity**

The lowest level of human cystatin C that can be detected by this assay is 0.23 ng/mL.

**B. Specificity**

The antibodies used in this assay are specific to human cystatin C and do not cross-react with mouse and rat cystatin C, and other cytokine or hormone molecules.

Website: [www.immunodiagnostics.com.hk](http://www.immunodiagnostics.com.hk)

E-mail: [info@immunodiagnostics.com.hk](mailto:info@immunodiagnostics.com.hk)(HK) /[info@immunodiagnostics.ca](mailto:info@immunodiagnostics.ca)(Canada)

Tel: +852 3502 2780 (HK) / +1-437-886-5136 (Canada)

### C. Precision

#### Intra-assay Precision (Precision within an assay)

Three samples of known concentration were tested 12 times on one plate.

Sample	Mean (ng/mL)	SD (ng/mL)	CV (%)
1	507.3	30.1	5.9
2	377.2	23.1	6.1
3	137.4	10.8	7.9

#### Inter-assay Precision (Precision between assays)

Three samples of known concentration were tested in 10 separate assays.

Sample	Mean (ng/mL)	SD (ng/mL)	CV (%)
1	499.3	39.0	7.8
2	377.2	23.1	6.1
3	137.4	10.8	7.9

### D. Recovery

Serum samples were spiked with different amounts of human cystatin C and assayed.

Sample	Average % Recovery	Range %
Serum	99	94-107

## REFERENCES

1. Stevens LA, Coresh J, Schmid CH, et al. (2008) *Am J Kidney Dis.* 51:395–406.
2. Dharnidharka VR, Kwon C, et al. (2002) *Am. J. Kidney Dis.* 40 (2): 221–6.
3. Hermida J, Tutor JC. (2006) *Ther Drug Monit.* 28 (3): 326–31.
4. Zethelius B, Berglund L, et al. (2008) *N. Engl. J. Med.* 358 (20): 2107–16.
5. Ix JH, Shlipak MG, Chertow GM, et al. (2007) *Circulation* 115 (2): 173–9.
6. Deo R, Fyr CL, Fried LF, et al. (January 2008) *Am. Heart J.* 155 (1): 62–8.
7. Servais A, Giral P, Bernard M, et al. (2008) *Am. J. Med.* 121 (5): 426–32.
8. Mi W, Pawlik M, Sastre M, et al. (2007) *Nat. Genet.* 39 (12): 1440–2.
9. Kaeser SA, Herzog MC, et al. (2007) *Nat. Genet.* 39 (12): 1437–9.
10. Zurdel J, Finckh U, Menzer G, et al. (2002) *Br J Ophthalmol* 86 (2): 214–9.
11. Strojjan P, Oblak I, Svetic B, et al. (2004) *Br. J. Cancer* 90 (10): 1961–8.
12. Kos J, Krasovec M, Cimerman N, et al. (2000) *Clin. Cancer Res.* 6 (2): 505–11.

**SUMMARY OF ASSAY PROCEDURE**

